Los Angeles Capital Management LLC Boosts Stock Position in Cerus Corporation $CERS

Los Angeles Capital Management LLC raised its holdings in Cerus Corporation (NASDAQ:CERS) by 30.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 367,389 shares of the biotechnology company’s stock after buying an additional 85,835 shares during the period. Los Angeles Capital Management LLC owned about 0.19% of Cerus worth $518,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in CERS. Acadian Asset Management LLC raised its position in shares of Cerus by 112.5% during the 1st quarter. Acadian Asset Management LLC now owns 1,898,621 shares of the biotechnology company’s stock worth $2,637,000 after acquiring an additional 1,005,079 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd increased its stake in Cerus by 140.2% in the second quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 367,525 shares of the biotechnology company’s stock valued at $518,000 after purchasing an additional 214,515 shares during the last quarter. Rhumbline Advisers raised its holdings in Cerus by 5.5% during the first quarter. Rhumbline Advisers now owns 251,907 shares of the biotechnology company’s stock worth $350,000 after purchasing an additional 13,112 shares in the last quarter. R Squared Ltd lifted its position in shares of Cerus by 106.7% during the 1st quarter. R Squared Ltd now owns 38,655 shares of the biotechnology company’s stock worth $54,000 after buying an additional 19,955 shares during the last quarter. Finally, CWM LLC lifted its position in shares of Cerus by 36.3% during the 2nd quarter. CWM LLC now owns 110,654 shares of the biotechnology company’s stock worth $156,000 after buying an additional 29,483 shares during the last quarter. 78.37% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Wall Street Zen raised shares of Cerus from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cerus in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $4.00.

Cerus Stock Performance

Shares of Cerus stock opened at $1.62 on Friday. The firm’s fifty day simple moving average is $1.50 and its 200-day simple moving average is $1.39. Cerus Corporation has a 12 month low of $1.12 and a 12 month high of $2.24. The stock has a market capitalization of $311.18 million, a price-to-earnings ratio of -16.20 and a beta of 1.67. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.00 and a quick ratio of 1.35.

Cerus (NASDAQ:CERS) last issued its quarterly earnings results on Thursday, November 6th. The biotechnology company reported $0.00 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.02. The firm had revenue of $60.24 million during the quarter, compared to analysts’ expectations of $55.12 million. Cerus had a negative net margin of 9.81% and a negative return on equity of 33.77%. Cerus has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Cerus Corporation will post -0.08 earnings per share for the current year.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.